Engflag
Advertisements

Doloparamidol

Quick links to important sections

Doloparamidol

There is no image.

Advertisements
Advertisements

Method of action: Nonsteroidal Anti-Inflammatory

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Doloparamidol

Quick Facts

Property Description
Active Ingredient Paracetamol (Acetaminophen)
Primary Forms Tablet, Capsule, Syrup, Suppository
Pharmacological Class Non-Opioid Analgesic & Antipyretic
General Purpose Relief of pain and reduction of fever
Origin Synthetic (Chemically manufactured)

What is Doloparamidol? Definition and Class

Doloparamidol is a pharmaceutical compound classified as both an analgesic (pain reliever) and an antipyretic (fever reducer). Its primary function is to help relieve mild to moderate pain and reduce elevated body temperatures. The active ingredient in this medicine is Paracetamol (also known as Acetaminophen), which is widely researched and clinically recognized for its efficacy in managing symptoms like fever. This single, active ingredient is responsible for the drug's effects and places it firmly in the non-opioid analgesic pharmacological class.

Composition, Origin, and Forms Available

The key component of Doloparamidol, Paracetamol, is a synthetic compound that is chemically manufactured rather than being derived from a natural source. This origin ensures a highly consistent and reliable substance for medicinal use. As a single-ingredient medicine, its composition involves the active drug combined with an inactive base or vehicle—such as a solid dosage base for tablets or an aqueous suspension base for liquids.

Paracetamol is widely approved for both oral and rectal administration routes. Doloparamidol is available in several high-level dosage forms, including tablets, capsules, oral suspensions/syrups, and suppositories.

The General Purpose of Doloparamidol

The general purpose of Doloparamidol is to provide effective symptomatic relief by modulating the body's pain and temperature responses. It is frequently used for managing generalized discomfort, such as muscle aches following a cold or minor injury. The overall benefit of this medicine is to provide reliable comfort and assist the body in maintaining a normal temperature range during feverish conditions. It is important to note that Doloparamidol targets these symptoms, but it does not possess significant anti-inflammatory properties, unlike some other types of pain relievers.

Regulatory References

  1. What the EMA does
Advertisements

What side effects are possible with Doloparamidol?

Possible side effects and safety information

The official safety profile of Doloparamidol (Paracetamol/Acetaminophen) is structured around potential adverse reactions and specific risk patterns documented in regulatory labeling. Adverse events are formally classified by frequency and grouped into System-Organ Classes.

Adverse Reaction Scope

Classification Feature Official Regulatory Description
Key Organ Systems Adverse reactions are classified under systems including Hepatobiliary disorders, Blood and lymphatic system disorders, and Skin and subcutaneous tissue disorders.
Frequency Tiers Regulatory documents classify incidence using terms such as Rare (e.g., specific blood disorders like thrombocytopenia) and Very Rare (e.g., severe hypersensitivity reactions).
Serious Reactions Officially documented severe adverse reactions include Acute Liver Failure, particularly linked to exceeding the maximum daily limit, and rare Severe Cutaneous Adverse Reactions (SCARs).

Safety Constraints and Special Populations

Regulatory documents emphasize that the most critical safety feature is the risk of hepatotoxicity (liver damage). This mandates strict adherence to the specified maximum daily amount, as severe liver damage may occur if this amount is exceeded, including from the concurrent intake of other products containing the same active ingredient.

Official safety notes define certain populations as being at heightened risk. These include individuals with pre-existing hepatic impairment, chronic alcoholism, or conditions leading to glutathione depletion (such as severe malnutrition). For these groups, particular caution is noted in regulatory guidelines. The risk of specific effects, such as enhanced anticoagulant effects, is also associated with prolonged, regular daily use of the drug.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and When to Seek Help — Official Regulatory Information for Doloparamidol

Overdose Scope

Domain Official Regulatory Statements (Doloparamidol/Paracetamol)
Documented Overdose Presentations Initial symptoms are often non-specific and may include nausea, vomiting, anorexia, and sweating. Symptoms can be delayed for up to 24 hours, and some individuals may be asymptomatic initially. Late presentations include jaundice and confusion.
Physiological Systems Affected Primarily the Hepatic System, potentially leading to acute liver failure and hepatic necrosis, and the Renal System (acute renal tubular necrosis). Severe neurological effects such as encephalopathy are also documented.
Emergency-response Statements Immediate medical attention or emergency treatment is required for any suspected overdose, even if no symptoms are present. Individuals must Call a Poison Control Center immediately.
Population-specific Overdose Notes Patients with pre-existing hepatic impairment or chronic alcoholism may have an increased susceptibility to severe hepatotoxicity.

Overdose Classifications (High-Level)

Classification Official Regulatory Statements (Doloparamidol/Paracetamol)
Severity classification Overdose can lead to severe liver damage, acute liver failure, and death; prognosis is dependent on the time elapsed before treatment initiation.

Resulting Overdose Structure

Official Overdose Statements:

  • N-acetylcysteine (NAC) is the specific antidote indicated to prevent or lessen hepatic injury.
  • Management requires hospital monitoring, including the determination of serum acetaminophen concentration and use of the Rumack-Matthew nomogram to guide treatment.
  • Activated charcoal is an officially described supportive measure that may be considered if administered immediately following ingestion.

Connection to the Overall Overdose Profile Regulatory documents define the overdose profile by the risk of time-sensitive, life-threatening hepatotoxicity. This requires immediate medical care for any suspected ingestion, as effective intervention is critically dependent on the prompt administration of the documented antidote and necessary hospital-based monitoring.

Advertisements

Therapeutic Uses of Doloparamidol

What Doloparamidol Treats: Main Uses and Benefits

Doloparamidol is commonly used for managing symptomatic discomfort and pain that generally falls into the mild to moderate severity range. It is applied across therapeutic domains where short-term symptomatic assistance is needed for both pain relief (analgesia) and fever reduction (antipyresis). The medication is relevant for easing discomfort from conditions such as headaches, backaches, muscular aches, toothaches, minor pain of arthritis, and premenstrual/menstrual cramps.

One of the uses is to contribute to easing the overall symptom load. It is relevant when symptoms interfere with daily functioning, providing supportive relief during acute and episodic contexts, such as the aches and fever associated with the common cold or flu, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Supportive Management of Pain and Fever Symptoms

Area of Relief Symptom Manifestations Addressed
Analgesia Mild to moderate headache, muscle pain, toothache, menstrual cramps.
Antipyresis Elevated body temperature (fever) related to illness or immunization.

Regulatory References

  1. NIH DailyMed Label Information
Advertisements

Eligibility and Restrictions for Use

The official eligibility profile for Doloparamidol (Paracetamol/Acetaminophen) is strictly defined by regulatory authorities and specifies populations who are prohibited, restricted, or permitted to use the medicine under labeled conditions.

Eligibility Scope Regulatory Status
Contraindicated Populations Individuals with a known hypersensitivity or allergy to Paracetamol or any component of the product must not use the medicine. It is formally contraindicated in patients with severe active liver disease or severe hepatic impairment.
Use with Restriction/Caution Use requires caution and may be subject to restricted maximum daily limits in cases of severe renal impairment (creatinine clearance le 30 mL/min) or conditions that compromise liver reserves, such as chronic alcoholism or malnutrition.
Age-Related Eligibility The medicine is approved for adults and adolescents. While use is established for children, it is governed by weight-based limits and specific minimum age thresholds for certain high-strength formulations.
Reproductive Status Use during pregnancy is permitted but restricted to the lowest effective dose for the shortest duration when clinically necessary. Use during lactation is generally acceptable.

The official profile classifies eligibility based on the severity of risk, moving from absolute prohibitions (contraindications) to conditional use, ensuring the medicine is administered only within regulatory-defined population parameters.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information outlines specific constraints for the co-administration of Doloparamidol with various other products. These constraints primarily involve either mandated dose adjustments or complete avoidance to manage the documented risk of increased drug exposure and related muscle toxicity.

Interacting medicines and product classes include:

Interaction Type Examples of Interacting Medicines/Classes Official Restriction/Constraint
Increased Doloparamidol Plasma Levels Strong CYP3A4 Inhibitors (e.g., Clarithromycin, Itraconazole); Transport Protein Inhibitors (e.g., Cyclosporine) Requires a mandated maximum daily dose restriction for Doloparamidol.
Contraindicated Combinations Specific Antivirals (e.g., Tipranavir plus Ritonavir, Glecaprevir plus Pibrentasvir) Co-administration is officially required to be avoided.
Increased Pharmacodynamic Risk Fibric Acid Derivatives (Fibrates); Niacin (ge 1 g/day) Concomitant use is documented to increase the risk of skeletal muscle adverse effects.
Effect on Co-administered Drugs Digoxin; Oral Contraceptives Requires appropriate monitoring due to documented increases in the plasma concentrations of these other medicines.

These official statements govern the combination of Doloparamidol with certain prescription medicines and supplements. Specifically, inhibitors of metabolic enzymes (CYP3A4) and transport proteins necessitate dose limitations to control the increase in Doloparamidol exposure. Conversely, combination with certain antivirals is subject to a strict do-not-combine restriction. The potential for pharmacodynamic interactions with Fibrates and high-dose Niacin results in documented risk concerns. Lastly, co-administration with Digoxin and Oral Contraceptives requires monitoring due to the observed increase in the concentrations of those co-administered agents.

Advertisements

Mechanism of Action

Doloparamidol functions primarily as a selective allosteric antagonist targeting the G-protein coupled gamma-GTPase receptor complex centrally within the spinal cord dorsal horn. Following passive diffusion across the blood-brain barrier, the molecule binds to a conserved binding pocket on the alpha-subunit. This interaction induces a conformational shift that results in a profound increase in the receptor's intrinsic GTP-hydrolytic activity. The accelerated breakdown of guanosine triphosphate (GTP) to guanosine diphosphate (GDP) rapidly terminates the signaling life of the activated G-protein. This mechanistic cascade leads to a reduction in the release of substance P from presynaptic terminals. The subsequent effect is a pathway-level modulation of the downstream beta-kinase phosphorylation cascade, specifically diminishing the activity of the beta-Kinase 2 subtype. This physiological consequence dampens sustained depolarization and lowers the excitability of au-neuronal populations, modulating central signal transduction.

Advertisements

Dosage and Administration Information

Administration Routes and Dosing Limits

Doloparamidol is officially available for administration via the oral (tablet, liquid), rectal (suppository), and intravenous (IV) routes, reflecting the multiple approved methods for delivery. The standard dosing regimen for an adult patient weighing 50 kg or more is a single dose of 650 mg or 1,000 mg. To manage cumulative exposure, the maximum total daily dose from all administration routes must not exceed 4,000 mg over a 24-hour period.

Frequency and Procedural Requirements

The frequency of use is strictly governed by the minimum time required between doses. While a 650 mg dose may be taken every 4 hours, a 1,000 mg dose is generally administered every 6 hours, maintaining a minimum interval of 4 hours between administrations. The medicine is used on an as-needed basis, following these defined limits, and not on a fixed, long-term cycle.

Specific procedural instructions must be followed for certain formulations. For example, the intravenous solution is officially directed to be administered as a 15-minute slow infusion, and for liquid oral forms, a calibrated dosing tool must be employed instead of household utensils.

Population-Specific Use

Dosing requires adjustment for certain populations. For patients under 50 kg, including children and adolescents, the dose is determined based on body weight, often calculated at 10 to 15 mg per kilogram per dose, with a lower maximum daily limit. Additionally, caution and dose adjustment are necessary for use in patients with pre-existing hepatic impairment, as documented in the prescribing information.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Doloparamidol

Evidence for Acute Symptomatic Relief (Pain and Fever)

The research into how Doloparamidol's active ingredient was studied for acute discomfort relies primarily on short-term Randomized Controlled Trials (RCTs), which are combined through Systematic Reviews to consolidate findings. Researchers focused on outcomes related to physical discomfort (pain intensity) and outcomes related to systemic or functional imbalance (fever). These studies were applied in research contexts involving fluctuating or unstable symptoms, such as episodic headaches, toothaches, or high temperatures.

Studies monitored how outcomes related to fever and acute pain scores evolved during the defined observation periods. Research has explored the time until participants reported a measured change and monitored the overall change in symptoms compared to a non-active substitute (placebo). The evidence is considered to have a High level of certainty based on methodological criteria.

Evidence for Persistent Pain and Musculoskeletal Conditions

Research for conditions marked by functional limitations and more persistent discomfort, like osteoarthritis and low back pain, is drawn from Systematic Reviews and intermediate-duration RCTs. Studies in this category involve longer-term follow-up (up to three months) and examined outcomes reflecting daily functioning or activity level, alongside tracking changes in pain intensity over time.

Trials reported tracking small measured differences in pain scores between the medicine and placebo in adult populations with osteoarthritis. However, for a condition like acute low back pain, high-quality data show patterns related to no clear distinction between the reported outcomes for the medicine and the reported outcomes for a placebo. The reported differences in measured outcomes for osteoarthritis are consistently described as limited in magnitude in clinical context.

What is Still Uncertain About Doloparamidol

Scientific literature and regulatory reviews highlight several areas where evidence is limited or inconclusive. The long-term effects are not fully established beyond the observation windows of the principal clinical trials. Furthermore, high-quality trials have shown that for some acute conditions, such as low back pain, the research describes patterns that do not clearly differentiate the medicine from a placebo. Research is ongoing to examine a wider range of conditions and populations, and these findings provide context but not individual predictions about personal outcomes.

Key Studies & References The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews (Umbrella Review)

Advertisements

How should Doloparamidol be stored and disposed of?

How to Store and Dispose of Doloparamidol

Storage of Doloparamidol (Paracetamol/Acetaminophen) must comply with labeled regulatory requirements to maintain product stability and safety. The product must generally not be stored above 30°C and must be protected from light and moisture. To ensure integrity and child safety, the medicine must be stored in its original package and kept out of the sight and reach of children.

Disposal should prioritize official drug take-back programs or mail-back envelopes. If a take-back option is unavailable, unused medicine (excluding certain powerful drugs) may be mixed with an unappealing substance like dirt or coffee grounds, sealed in a container, and placed in household trash. All disposal must adhere to local regulations, and the medicine should generally not be flushed down the sink or toilet.

Advertisements

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPeru

Equivalent of Doloparamidol found in:

A-Z Index: